IMMUNIC, INC.

Immunic is a biotechnology company developing selective oral immunology therapies targeting chronic inflammatory and autoimmune diseases. The company's pipeline focuses on modulating immune responses to treat conditions including multiple sclerosis, ulcerative colitis, and gastrointestinal disorders. Its approach emphasizes oral drug delivery, which may offer advantages in patient compliance and convenience compared to injectable alternatives.

The lead program, IMU-838, is advancing through Phase 3 clinical trials for relapsing and progressive multiple sclerosis and Phase 2 development for moderate-to-severe ulcerative colitis. IMU-856, which is entering Phase 2 trials, targets intestinal barrier dysfunction in conditions such as celiac disease, inflammatory bowel disease, short bowel syndrome, and irritable bowel syndrome with diarrhea. A third candidate, IMU-381, remains in preclinical development for gastrointestinal diseases.

Immunic was incorporated in Delaware and founded in 2016, with headquarters in New York and operations in Germany. As a clinical-stage biotechnology company, the organization is primarily funded through equity financing and does not generate significant product revenues. The company operates within the pharmaceutical preparations industry, competing in the immunology and gastroenterology therapeutic spaces.